Cytolon Partners with CSC to Develop CordMatch^®

Berlin, January 29, 2010 – Cytolon AG announced today the signing of an agreement with CSC for the rapid development of Cytolon's CordMatch^® platform. This platform will enable patients who need transplantation to get the correct, best-matched cord blood unit (CBU) promptly.

Thomas Klein, founder and CEO of Cytolon AG, stated, "CSC was chosen during a comprehensive competition among more than a dozen excellent candidates because of its capabilities and expertise in health IT, as well as its support of this specific project." Furthermore, Klein added, "Cytolon is proud to work with a company that is one of the top leaders in the healthcare information technology field, and the excellent team at CSC will be essential to our success as we move forward with our CordMatch^® platform."

"CSC is pleased to work with Cytolon on this platform that allows providing opportune life-saving therapy to patients. As CSC is transforming healthcare with better information for better decisions, we are using technology to help cord blood transplantation patients and doctors by delivering critical information," said Robert Wah, MD, Chief Medical Officer and vice president of Government Health Services, CSC North American Public Sector.


About CSC:
CSC is a global leader in providing technology-enabled solutions and services through three primary lines of business. These include Business Solutions and Services, the Managed Services Sector and the North American Public Sector. CSC's advanced capabilities include systems design and integration, information technology and business process outsourcing, applications software development, Web and application hosting, mission support and management consulting. Headquartered in Falls Church, Va., CSC has approximately 92,000 employees and reported revenue of US$16.0 billion for the 12 months ended October 2, 2009. For more information, visit the company's Web site at www.csc.com.


About Cytolon AG:
Cytolon AG is a private Company based in Berlin, Germany that has developed a proprietary, patent-pending, global, internet-based cord blood brokering platform termed CordMatch^®. This platform is positioned to profit from the crossroad of the personal data and cellular therapeutic markets of regenerative medicine. Cytolon's mission is to be the world's first trusted source for getting the correct, best-matched cord blood unit (CBU) to the patient that needs it in a timely manner. An accurate cord blood matching platform is imperative as a CBU must accurately match the histocompatibility antigens and the genetic needs of the patient. Cytolon provides solutions and services for today and the future so world-wide transplant centers can talk efficiently and effectively to world-wide cord blood banks, registries, industry partners and service providers. Cytolon focuses on penetrating immediate and emerging markets in the cord blood and stem cell area. For more information, please visit the company's Web site at www.cytolon.com.

Contact:
Nina Hofle - PR Manager
Cytolon AG

Am Karlsbad 15
10785 Berlin - Germany

phone: +49 (0) 30 2639 288-0
fax: +49 (0) 30 2639 288-20
e-mail: info@cytolon.com
web: www.cytolon.com